Compare Regeneron Pharmaceuticals Inc (REGN) vs United Airlines Holdings Inc (UAL) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.

The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.

United Airlines (UAL) trades at $107.44, down 2.48% on the day, reflecting near-term pressure amid a bearish technical signal. Fundamentally, the company shows strength with a low P/E of 10.06, robust ROE of 23.25%, and consistent earnings beats in recent quarters. Recent news highlights aggressive customer acquisition efforts targeting Delta and American Airlines' premium flyers, leveraging Starlink WiFi partnerships to enhance its competitive edge.

The outlook is mixed: strong analyst consensus (66% buy ratings) and a $158.10 price target suggest upside, but rising fuel costs and bearish technicals pose near-term risks. Earnings sustainability and market share gains from strategic moves are key catalysts, while volatility in travel demand remains a headwind.